173 related articles for article (PubMed ID: 32593231)
1. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
D'Orazi G; Garufi A; Cirone M
IUBMB Life; 2020 Aug; 72(8):1634-1639. PubMed ID: 32593231
[TBL] [Abstract][Full Text] [Related]
2. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HIF-1alpha activity by homeodomain-interacting protein kinase-2 correlates with sensitization of chemoresistant cells to undergo apoptosis.
Nardinocchi L; Puca R; Sacchi A; D'Orazi G
Mol Cancer; 2009 Jan; 8():1. PubMed ID: 19128456
[TBL] [Abstract][Full Text] [Related]
4. A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status.
Garufi A; Baldari S; Pettinari R; Gilardini Montani MS; D'Orazi V; Pistritto G; Crispini A; Giorno E; Toietta G; Marchetti F; Cirone M; D'Orazi G
J Exp Clin Cancer Res; 2020 Jun; 39(1):122. PubMed ID: 32605658
[TBL] [Abstract][Full Text] [Related]
5. Targeting hypoxia in cancer cells by restoring homeodomain interacting protein-kinase 2 and p53 activity and suppressing HIF-1alpha.
Nardinocchi L; Puca R; Sacchi A; Rechavi G; Givol D; D'Orazi G
PLoS One; 2009 Aug; 4(8):e6819. PubMed ID: 19714248
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses.
Torrente L; Sanchez C; Moreno R; Chowdhry S; Cabello P; Isono K; Koseki H; Honda T; Hayes JD; Dinkova-Kostova AT; de la Vega L
Oncogene; 2017 Nov; 36(44):6204-6212. PubMed ID: 28692050
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of HIPK2 circumvents the blockade of apoptosis in chemoresistant ovarian cancer cells.
Puca R; Nardinocchi L; Pistritto G; D'Orazi G
Gynecol Oncol; 2008 Jun; 109(3):403-10. PubMed ID: 18395248
[TBL] [Abstract][Full Text] [Related]
8. HIPK2-a therapeutical target to be (re)activated for tumor suppression: role in p53 activation and HIF-1α inhibition.
Nardinocchi L; Puca R; Givol D; D'Orazi G
Cell Cycle; 2010 Apr; 9(7):1270-5. PubMed ID: 20234185
[TBL] [Abstract][Full Text] [Related]
9. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
[TBL] [Abstract][Full Text] [Related]
10. The Impact of NRF2 Inhibition on Drug-Induced Colon Cancer Cell Death and p53 Activity: A Pilot Study.
Garufi A; Pistritto G; D'Orazi V; Cirone M; D'Orazi G
Biomolecules; 2022 Mar; 12(3):. PubMed ID: 35327653
[TBL] [Abstract][Full Text] [Related]
11. Negative regulation of beta4 integrin transcription by homeodomain-interacting protein kinase 2 and p53 impairs tumor progression.
Bon G; Di Carlo SE; Folgiero V; Avetrani P; Lazzari C; D'Orazi G; Brizzi MF; Sacchi A; Soddu S; Blandino G; Mottolese M; Falcioni R
Cancer Res; 2009 Jul; 69(14):5978-86. PubMed ID: 19567674
[TBL] [Abstract][Full Text] [Related]
12. HIPK2 modulates p53 activity towards pro-apoptotic transcription.
Puca R; Nardinocchi L; Sacchi A; Rechavi G; Givol D; D'Orazi G
Mol Cancer; 2009 Oct; 8():85. PubMed ID: 19828042
[TBL] [Abstract][Full Text] [Related]
13. Hyperglycemia triggers HIPK2 protein degradation.
Baldari S; Garufi A; Granato M; Cuomo L; Pistritto G; Cirone M; D'Orazi G
Oncotarget; 2017 Jan; 8(1):1190-1203. PubMed ID: 27901482
[TBL] [Abstract][Full Text] [Related]
14. HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage.
Lazzari C; Prodosmo A; Siepi F; Rinaldo C; Galli F; Gentileschi M; Bartolazzi A; Costanzo A; Sacchi A; Guerrini L; Soddu S
Oncogene; 2011 Dec; 30(48):4802-13. PubMed ID: 21602882
[TBL] [Abstract][Full Text] [Related]
15. HIF-1α antagonizes p53-mediated apoptosis by triggering HIPK2 degradation.
Nardinocchi L; Puca R; D'Orazi G
Aging (Albany NY); 2011 Jan; 3(1):33-43. PubMed ID: 21248371
[TBL] [Abstract][Full Text] [Related]
16. Homeodomain-interacting protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis.
Di Stefano V; Rinaldo C; Sacchi A; Soddu S; D'Orazi G
Exp Cell Res; 2004 Feb; 293(2):311-20. PubMed ID: 14729469
[TBL] [Abstract][Full Text] [Related]
17. Counteracting MDM2-induced HIPK2 downregulation restores HIPK2/p53 apoptotic signaling in cancer cells.
Nardinocchi L; Puca R; Givol D; D'Orazi G
FEBS Lett; 2010 Oct; 584(19):4253-8. PubMed ID: 20849851
[TBL] [Abstract][Full Text] [Related]
18. HIPK2 overexpression relieves hypoxia/reoxygenation-induced apoptosis and oxidative damage of cardiomyocytes through enhancement of the Nrf2/ARE signaling pathway.
Dang X; Zhang R; Peng Z; Qin Y; Sun J; Niu Z; Pei H
Chem Biol Interact; 2020 Jan; 316():108922. PubMed ID: 31837296
[TBL] [Abstract][Full Text] [Related]
19. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.
Puca R; Nardinocchi L; Bossi G; Sacchi A; Rechavi G; Givol D; D'Orazi G
Exp Cell Res; 2009 Jan; 315(1):67-75. PubMed ID: 18996371
[TBL] [Abstract][Full Text] [Related]
20. Updates on HIPK2: a resourceful oncosuppressor for clearing cancer.
D'Orazi G; Rinaldo C; Soddu S
J Exp Clin Cancer Res; 2012 Aug; 31(1):63. PubMed ID: 22889244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
